• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Necrotizing pancreatitis, microangiopathic hemolytic anemia and thrombocytopenia following the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine
We report a 31-year-old female with a history of borderline personality disorder, intravenous drug abuse, allergic asthma, eating disorder, psoriatic arthritis treated with tofacitinib, neurogenic bladder disturbance, cholecystectomy, recurrent thoracic herpes zoster, vaginal candida infections and urinary tract infections, who developed pancreatitis associated with thrombotic microangiopathy and hemolytic-uremic syndrome 10 days after the second vaccination, whereas the first has been well tolerated. She was treated by plasma exchange, and eventually by transgastric drainage with implantation of a plastic stent to remove ...
Source: Wiener Klinische Wochenschrift - June 6, 2023 Category: General Medicine Authors: Claudia St öllberger Kastriot Kastrati Clemens Dejaco Martina Scharitzer Josef Finsterer Patrick Bugingo Madeleine Melichart-Kotik Astrid Wilfing Source Type: research

A Case Report of Herpes Zoster Ophthalmicus and Meningitis After COVID-19 Vaccination
J Korean Med Sci. 2022 May 23;37(20):e165. doi: 10.3346/jkms.2022.37.e165.ABSTRACTThere are several reports that herpes zoster characterized by reactivation of varicella zoster virus (VZV) following coronavirus disease 2019 (COVID-19) vaccines can occur. Herein, we report VZV meningitis, herpes zoster ophthalmicus (HZO), and late neurotrophic keratitis after receiving a second dose of messenger RNA (mRNA) COVID-19 vaccine. A 74-year-old man developed a vesicular skin rash on the forehead, scalp, nose, and left upper eyelid with a severe headache. Five days earlier, he received a second dose of the BNT162b2 mRNA vaccine on ...
Source: J Korean Med Sci - May 24, 2022 Category: General Medicine Authors: In-Cheon You Min Ahn Nam-Chun Cho Source Type: research

Complications and cost estimations in herpes zoster - a retrospective analysis at a Swiss tertiary dermatology clinic
CONCLUSION: In this herpes zoster population at a university hospital, one in three patients was affected by herpes zoster-related complications. Age and cancer were independently associated with a high complication rate, suggesting a need to vaccinate cancer patients. Herpes zoster-related complications and the need for inpatient treatment escalated the costs per case.PMID:34964592 | DOI:10.4414/smw.2021.w30081
Source: Swiss Medical Weekly - December 29, 2021 Category: General Medicine Authors: Leonard D Bongers Alexander Navarini Christoph T Berger Simon M Mueller Source Type: research

Healthcare workers' perceptions and experiences of communicating with people over 50 years of age about vaccination: a qualitative evidence synthesis
CONCLUSIONS: There is little research focusing specifically on healthcare workers' perceptions and experiences of communication with older adults about vaccination. The studies we identified suggest that healthcare workers differed among themselves in their perceptions about the aim of this communication and about the role of older adults in vaccine decisions. Based on these findings and the other findings in our review, we have developed a set of questions or prompts that may help health system planners or programme managers when planning or implementing strategies for vaccination communication between healthcare workers ...
Source: Cochrane Database of Systematic Reviews - July 20, 2021 Category: General Medicine Authors: Claire Glenton Benedicte Carlsen Simon Lewin Manuela Dominique Wennekes Brita Askeland Winje Renske Eilers VITAL consortium Source Type: research

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: LZV and RZV are effective in preventing herpes zoster disease for up to three years (the main studies did not follow participants for more than three years). To date, there are no data to recommend revaccination after receiving the basic schedule for each type of vaccine. Both vaccines produce systemic and injection site adverse events of mild to moderate intensity. PMID: 31696946 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 6, 2019 Category: General Medicine Authors: Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, Canteiro Cruz E Tags: Cochrane Database Syst Rev Source Type: research

Pages: 1  2